In 2018, the global pharmaceutical industry stood at $1.2 trillion, and experts expect $1.5 trillion by 2023. Here’s everything investors need to know.
The Healthcare Select Sector SPDR ETF’s (XLV) price has increased ~14.6% in the third quarter, and its year-to-date returns increased ~15.5% on October 2.
Leading pharmaceutical company Allergan (AGN), which deals in generic and specialty pharmaceutical products, segregated its business into three segments: US General Medicines, US Specialized Therapeutics, and International.
On January 22, Vermont decriminalized the possession of marijuana for adults 21 and older. Vermont became the ninth state to legalize marijuana for recreational purposes.
Pfizer’s performance As discussed earlier, Pfizer (PFE) had a top line of $13.2 billion in 3Q17. Whereas its US sales were nearly flat, its international sales saw 3% operational growth. Overall, Pfizer’s revenue grew 1% during 3Q17, marginally impacted by foreign exchange. The US markets The above chart compares Pfizer’s segment-wise US and international revenue in 3Q17. It […]
In 3Q17, Valeant’s (VRX) Arestin reported revenues of $26 million, which was ~7% lower on a YoY (year-over-year) basis and 7% lower quarter-over-quarter.
In 3Q17, Valeant Pharmaceuticals generated revenues of $2.2 billion, which was ~10% lower YoY (year-over-year) and 1% lower QoQ (quarter-over-quarter).
Johnson & Johnson’s (JNJ) gross profit margin decreased to 64.9% during 3Q17, a decline of ~4.0% compared to the gross profit margin of 69.2% during 3Q16.
Analysts’ estimates Analysts expect Gilead Sciences’ (GILD) top line to fall 15% to ~$25.8 billion in 2017, and forecast EPS (earnings per share) of $8.70. The above chart shows analysts’ recommendations over the last 12 months. Analysts expect EPS of $1.69 and revenue of $5.7 billion in 4Q17. Analysts’ ratings Gilead Sciences’ stock price has risen ~1.9% over […]
The oncology portfolio Bristol-Myers Squibb’s (BMY) oncology portfolio includes key products Empliciti, Opdivo, Sprycel, and Yervoy. The oncology portfolio contributes over 40% of Bristol-Myers Squibb’s total revenue. Empliciti The above chart compares key oncology products’ revenue over the last few quarters. Empliciti is the latest drug launched by Bristol-Myers Squibb for the treatment of multiple myeloma. […]
In February 2017, the FDA (Food and Drug Administration) approved Valeant Pharmaceuticals’ (VRX) Siliq injection for the treatment of adults with moderate to severe plaque psoriasis.
In 3Q17, Eli Lilly’s (LLY) Olumiant (baricitinib) reported revenues of $16.2 million compared to $4.8 million and $1.9 million in 2Q17 and 1Q17, respectively.
In 3Q17, Eli Lilly’s overall revenues from oncology products fell due to lower sales of Alimta, Erbitux, and Portrazza, offset by a rise in Cyramza sales.
Bridion revenue In 3Q17, Merck’s (MRK) Bridion reported revenue of $185 million, which reflected ~33% growth YoY (year-over-year) and 13% growth QoQ (quarter-over-quarter). During the first nine months of 2017, Bridion generated revenue of $495 million, which reflected 44% growth YoY. Growth in US sales volumes primarily contributed to the drug’s revenue growth in the two […]
Immunology drug revenue In 3Q17, Remicade generated revenue of $214 million, a ~31% fall YoY (year-over-year) and 3% growth QoQ (quarter-over-quarter). During the first nine months of 2017, Remicade reported revenue of $651 million, which reflected a ~35% fall YoY. Foreign exchange had a 3% favorable effect towards 3Q17 Remicade revenue. In 3Q17, Simponi reported revenue of […]
The latest report was released on November 3 and indicated that the goods and services deficit was $43.5 billion in September, or $0.7 billion higher than in August.
In 1H17, Valeant Pharmaceuticals International’s (VRX) U.S. Diversified Products franchise reported revenues of $519.0 million compared to $848.0 million in 1H17.
In 1H17, Valeant Pharmaceuticals International (VRX) reported revenues of $4.3 billion compared to $4.7 billion in 1H16. In 2Q17, its revenues were $2.2 billion.
Eli Lilly (LLY) reported growth of 8.0% in its 2Q17 revenues to $5.8 billion compared to 2Q16. Analysts estimate revenues of $5.5 billion for 3Q17, a 6.1% rise compared to 3Q16.
On July 31, 2017, Eli Lilly and Boehringer Ingelheim announced that the companies would support one of the new programs by the American College of Cardiology.
Forteo is used for the treatment of osteoporosis. Forteo’s sales totaled $446.7 million during 2Q17, a 22.0% increase compared to $367.6 million in 2Q16.
In August 2017, the Arthritis Advisory Committee of the FDA recommended a positive opinion for the proposed dose of Xeljanz for the treatment of individuals with active psoriatic arthritis.
In 2Q17, Chantix/Champix generated revenues of ~$248 million, which represents ~16% growth on a YoY basis and 4% growth on a quarter-over-quarter basis.
In 2Q17, Jazz Pharmaceuticals’ (JAZZ) Xyrem reported revenues of ~$298 million, which represented a YoY (year-over-year) growth of ~6% and sequential growth of ~9%.
The key products in Bristol-Myers Squibb’s (BMY) oncology portfolio include Empliciti, Opdivo, Sprycel, and Yervoy. Let’s take a closer look at these drugs and their performances.
In March 2017, the FDA approved Regeneron and Sanofi’s Dupixent injection for the treatment of adult individuals with moderate to severe atopic dermatitis.
A look at Bristol-Myers Squibb Headquartered in New York City, Bristol-Myers Squibb (BMY) is an American pharmaceutical company that develops innovative medicines in various therapeutic areas, including cardiovascular, neuroscience, immunoscience, oncology, and virology. Stock price performance While Bristol-Myers Squibb’s stock price has risen ~3.8% in 2Q17, it had fallen ~5.4% year-to-date as of July 7, […]
Merck (MRK) launched Keytruda in 4Q14 and reported global sales of $584 million for 1Q17. As a result, the company reported ~134% growth in revenues compared to $249 million in 1Q16.
Pfizer (PFE) reported a 2.0% fall in 1Q17 revenues to ~$12.8 billion, with a 1.0% operational fall in revenues and a 1.0% negative impact of foreign exchange.
JNJ’s overall business is classified into three segments: Pharmaceuticals, Consumer, and Medical Devices. At constant exchange rates, the company reported growth across all of its segments.
